NSILA-S, physiologic and pharmacologic significance as an insulinlike hormone and as a growth-promoting hormone.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to U Schlumpf.
Explore the source record for details and available documents.
Intravenous pulse methylprednisolone of 1000 mg was compared with 250 mg in patients suffering from rheumatoid arthritis. In this prospective open trial no difference could be observed regarding the number of heavily involved joints, morning stiffness, or blood sedimentation rate 2 weeks and 2 months after use of highdose or intermediate dose intravenous methylprednisolone. Medium remission duration was 6 weeks (2-24 weeks). Side effects occurred only rarely; they were transitory and harmless.
The problem in handling child-resistant containers for patients suffering from rheumatoid arthritis especially in advanced stage and in the elderly may be underestimated. The negative influence of blister packaging on compliance may be of major importance. The technically insufficient containers of drugs for rheumatoid patients are explained and alternative solutions are briefly discussed.